Brock v. Merrell Dow Pharmaceuticals, Inc., 88-2311
| Decision Date | 15 August 1989 |
| Docket Number | No. 88-2311,88-2311 |
| Citation | 884 F.2d 166 |
| Parties | Mr. & Mrs. Floyd BROCK, individually and as next friend of Rachel Brock, a minor, Plaintiffs-Appellees, v. MERRELL DOW PHARMACEUTICALS, INC., Defendant-Appellant. |
| Court | U.S. Court of Appeals — Fifth Circuit |
Appeal from the United States District Court for the Eastern District of Texas, William M. Steger, Judge.
ON PETITION FOR REHEARING
Before GARZA, JOLLY, and JONES, Circuit Judges.
Appellees have filed a petition for rehearing en banc with regard to our prior disposition of this case, Brock v. Merrell Dow Pharmaceuticals, Inc., 874 F.2d 307, 308 (5th Cir.1989). Treating that petition as a petition for panel rehearing, we hereby modify our prior panel opinion.
At 313, we stated that "[w]e find, in this case, the lack of conclusive epidemiological proof to be fatal to the Brocks' case." We hereby change that sentence to read "[w]e find, in this case, the Brocks' failure to present statistically significant epidemiological proof that Bendectin causes limb reduction defects to be fatal to their case."
We also change the last two sentences of the second to last paragraph on 315, which read:
Hopefully, our decision will have the effect of encouraging district judges faced with medical and epidemiologic proof in subsequent toxic tort cases to be especially vigilant in scrutinizing the basis, reasoning, and conclusiveness of studies presented by both sides. However, we do not wish this case to stand as a bar to future Bendectin cases in the event that new and conclusive studies emerge which would give a jury a firmer basis on which to determine the issue of causation.
These sentences should read as follows:
Hopefully, our decision will have the effect of encouraging district judges faced with medical and epidemiologic proof in subsequent toxic tort cases to be especially vigilant in scrutinizing the basis, reasoning, and statistical significance of studies presented by both sides. However, we do not wish this case to stand as a bar to future Bendectin cases in the event that new and statistically significant studies emerge which would give a jury a...
To continue reading
Request your trial
-
Werlein v. US
...aff'd on other grounds, 818 F.2d 187 (2d Cir.1987) and Brock v. Merrell Dow Pharmaceuticals, Inc., 874 F.2d 307 (5th Cir.), modified 884 F.2d 166, rehearing denied, 884 F.2d 167 (5th Cir.1989) for the proposition that epidemiological proof is necessary to establish legal In Agent Orange, Vi......
-
Maritime Overseas Corp. v. Ellis
...fifth circuit cases. Brock v. Merrill Dow Pharmaceuticals, Inc., 874 F.2d 307 (5th Cir.1989) (Brock I); Brock v. Merrill Dow Pharmaceuticals, Inc., 884 F.2d 166 (5th Cir.1989) (Brock II); Christophersen v. Allied Signal Corp., 914 F.2d 66 (5th Cir.), reh. en banc, 939 F.2d 1106 (5th Cir.199......
-
Moore v. Ashland Chemical, Inc.
...U.S. 826, 113 S.Ct. 84, 121 L.Ed.2d 47 (1992); Brock v. Merrell Dow Pharmaceuticals, Inc., 874 F.2d 307 (5th Cir.1989), modified, 884 F.2d 166 (5th Cir.1989), cert. denied, 494 U.S. 1046, 110 S.Ct. 1511, 108 L.Ed.2d 646 f. The Daubert "factors" are hard scientific methods that generally are......
-
Maritime Overseas Corp. v. Ellis
...v. Havner, 953 S.W.2d 706 (Tex.1997).2 Maritime also cites Brock v. Merrell Dow Pharms., Inc., 874 F.2d 307 (5 th Cir.), modified, 884 F.2d 166 (1989), to support its argument that Ellis's experts' testimony was not proper scientific evidence. However, like Daubert, Robinson and Havner, in ......
-
Toxic apportionment: a causation and risk contribution model.
...to undertake studies to assess toxicological risks. (298) See Boston, supra note 14, at 381. (299) 874 F.2d 307 (5th Cir. 1988), modified, 884 F.2d 166 (5th Cir.), reh'g denied en banc, 884 F.2d 167 (5th Cir. 1989) (involving product liability for Bendectin). (300) 874 F.2d at 311. (301) Br......